Keeping Track: Psoriasis Gets New Topical In Arcutis’ Zoryve; Cidara Submits IV Antifungal
Executive Summary
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
Cidara’s Rezafungin: US FDA Panel Asked To Weigh ‘Limited Use’ Indication For Antifungal
Antimicrobial Drugs Advisory Committee will consider whether overall benefit-risk assessment is favorable for treatment of candidemia/invasive candidiasis in adults with limited or no treatment options and, if so, the clinical scenario in which rezafungin fulfills an unmet need.
Novel Brain Penetrant For Treating X-ALD Among Raft Of New EU Filings
Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.
ObsEva Ends Linzagolix Launch Plans, Casting Another Shadow Over Women's Health
The Swiss drug maker will initiate a "mass dismissal" and return rights to its lead drug candidate after the US FDA alerted the company to NDA deficiencies.